Likang Life Sciences to Present Personalized Cancer Immunotherapy Advances in Abu Dhabi
Likang Life Sciences will exhibit at the Abu Dhabi Future Health Summit 2026, showcasing its AI-powered personalized cancer immunotherapy development.
Biotechnology firm Likang Life Sciences will participate in the Abu Dhabi Future Health Summit 2026, held from October 20-22, to present its advancements in AI-driven personalized cancer immunotherapy.
Shannon Cheung, Likang's Co-Founder and Vice Chairman, is scheduled to speak on the "The Future of Cancer" panel on October 21. The discussion will focus on progress in precision oncology and the integration of novel cancer treatments into clinical settings.
The summit, convened by the Department of Health – Abu Dhabi, gathers global health sector leaders to discuss artificial intelligence, genomics, and personalized healthcare.
Likang Life Sciences is developing therapies targeting patient-specific tumor neoantigens. The company's lead investigational candidate, LK101, is a personalized neoantigen mRNA-DC therapeutic cancer vaccine that has received authorization for clinical trials in China and the U.S.
Through its participation, Likang Life Sciences aims to foster international scientific and clinical collaboration and accelerate the development of personalized cancer treatments.